[Long-term complete response in a patient with breast cancer and bone and pleura metastases after treatment with a combination of S-1 and zoledronic acid]

Gan To Kagaku Ryoho. 2010 Jul;37(7):1317-20.
[Article in Japanese]

Abstract

We report a long-term complete response (CR) in a patient with postoperative recurrent breast cancer and bone and pleura metastases after treatment with a combination of S-1 and zoledronic acid. We administered 4 courses of tri-weekly CE (epirubicin 75 mg/m2, cyclophosphamide 600 mg/m2) and 12 courses of weekly paclitaxel (80 mg/m2) as adjuvant chemotherapy. However, combination therapy with S-1 and zoledronic acid was started because of the development of bone and pleura metastases. S-1 was administered orally at 100 mg/day everyday for 2 weeks, followed by a 1-week rest interval as 1 course; 4 mg of zoledronic acid was injected every 4 weeks. After 3 cycles of treatment, the patient's tumor marker levels had decreased to normal values, and both the bone and pleura metastases had disappeared. A long-term complete response was obtained as a result of this combination therapy.

Publication types

  • Case Reports

MeSH terms

  • Biomarkers, Tumor / blood
  • Bone Density Conservation Agents / therapeutic use*
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / secondary
  • Breast Neoplasms / blood
  • Breast Neoplasms / diagnostic imaging
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Diphosphonates / therapeutic use*
  • Drug Combinations
  • Humans
  • Imidazoles / therapeutic use*
  • Oxonic Acid / therapeutic use*
  • Pleural Neoplasms / drug therapy*
  • Pleural Neoplasms / secondary
  • Tegafur / therapeutic use*
  • Time Factors
  • Tomography, X-Ray Computed
  • Zoledronic Acid

Substances

  • Biomarkers, Tumor
  • Bone Density Conservation Agents
  • Diphosphonates
  • Drug Combinations
  • Imidazoles
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid
  • Zoledronic Acid